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ABSTRACT
Background Chronic neuropathic pain is a com-
mon condition which is challenging to treat. Many
people with neuropathic pain are managed in the
community, so primary care records may allow
more appropriate subjects to be recruited for clini-
cal studies.
Objective We investigated whether primary care
records can be used to identify patients with dis-
eases associated with neuropathic pain.
Method We analysed demographic, diagnostic
and prescribing data from over 100 000 primary
care electronic patient records in one part of
London, UK.
Results The prevalence of diagnoses associated
with chronic neuropathic pain was 13 per 1000,
with the elderly, women and white patients experi-
encing the greatest burden of disease.
Conclusion Computerised health records oﬀer an
excellent opportunity to improve the identiﬁcation
of patients for clinical research in complex con-
ditions like chronic neuropathic pain. To make full
use of data from these records, standardisation of
clinical coding and consensus on diagnostic criteria
are needed.
Keywords: clinical research, electronic health rec-
ord, ‘medical records systems, computerised’, neur-
algia, neuropathic pain, prevalence, primary care,
treatment
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Introduction
Neuropathic pain arises ‘as a direct consequence of
a lesion or disease aﬀecting the somato-sensory sys-
tem’.1 It is common and debilitating, with signiﬁcant
societal impact.2 Despite the availability of eﬃcacious
treatments, chronic neuropathic pain remains a chal-
lenge to manage.3
Most studies of neuropathic pain have taken place
in patients referred to secondary care, or in diagnostic
subsets.4 However, as with other chronic conditions,
diagnosis and management increasingly occurs in the
community. Community prevalence estimates vary
from 3.3%5 to 17.9%6–8 depending on the method-
ology, disease subset and population studied, but the
overall prevalence among patients presenting to gen-
eral practice is unknown.4 Outlining the prevalence of
a condition can encourage research into diagnosis and
management.6
Most general practices in the UK now have com-
puterised medical record systems. These include exten-
sive longitudinal information on diagnoses, physical
measurements, investigations, prescriptions and refer-
rals. These records have mainly been used to study
conditions such as coronary heart disease, diabetes,
hypertension and epilepsy. Despite being complex,
multisystem disorders, their indicators tend to be
well-recorded. This may be in part due to the ﬁnancial
incentives in the Quality and Outcomes Framework9
and also because they are better understood and clas-
siﬁed, with well-deﬁned coding in electronic patient
records.
Electronic primary care records can be used to
improve clinical management and research in chronic
disease.10,11 We aimed to determine the feasibility of
using primary care records to identify patients with
neuropathic pain, and to describe how such patients
are managed pharmacologically in primary care.
Methods
Identiﬁcation of patients with
neuropathic pain
Brent is a West London urban area with 55% of its
population from non-native ethnic groups.12,13 The
population of Brent is younger and has higher levels of
unemployment than the rest of England. Twenty-six
of 79 general practitioner (GP) practices in the London
Borough of Brent contribute automatically extracted,
standardised electronic patient records to a central
database. Data from three general practices were not
suitable for analysis, leaving data from 23 general
practices with a registered population of over 100 000
patients.
Data include demographic and clinical information
using READ coding, which is the clinical classiﬁcation
system used in UK primary care.14 The information
extracted from the electronic records allowed patient-
level analyses by age, sex and ethnicity. Data were
extracted for the 2007 calendar year. The dataset con-
sisted of data ﬁles for each of the READ code 5-byte
(version 2) chapters A–Z, with additional data ﬁles for
ethnicity coding and general practice details. Each
consultation record contained details of the practice
number, local patient identiﬁcation number, READ
code, a 30-character description of the consultation,
the date of consultation, and age and sex of patient.
We identiﬁed READ code terms for conditions
associated with neuropathic pain (Appendix 1) and
searched the database for every patient with one or
more of those codes in their records.We also extracted
records of medications prescribed for these patients.
Data analysis
We examined the prevalence of neuropathic pain diag-
noses recorded under various READ code terms, by age,
sex, ethnicity, practice and selected co-morbidities.
Where this study ﬁts in
. Research into chronic neuropathic pain has mainly involved patients in secondary care.
. Many people with chronic neuropathic pain are managed in the community.
. We demonstrate how information about chronic neuropathic pain and its management can be derived
from primary care records.
What this paper adds
. Electronic primary care records are a useful resource for studying chronic neuropathic pain.
. In our diverse population, the prevalence of diagnoses associated with chronic neuropathic pain was 13 in
1000.
. There may be ethnic diﬀerences in the epidemiology of neuropathic pain.
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We also explored the proportion of patients taking
various analgesics and how this varied by age, sex,
ethnicity and diagnostic group (because the recom-
mended drug class depends on the underlying con-
dition15). Data were analysed using Microsoft Excel
2007 and Stata Version 10.
Results
The age–sex distribution of the patients in the
database was similar to that of Brent and London.
Ethnicity was recorded for 49% of patients; the ethnic
distribution reﬂected the Brent population accurately.
Prevalence of disorders likely to be
associated with neuropathic pain
Of the 105 877 patients with valid age and sex data,
1390 had at least one neuropathic pain-associated
diagnosis; an overall prevalence of about 13 per 1000
patients. There were 33 separate terms used for neuro-
pathic pain-associated disorders; the most common
terms were herpes zoster and its subcodes (Table 1).
The majority of codes were recorded for the elderly
and women (Table 2). Prevalence varied by ethnicity,
with the highest prevalence in white patients (Figure 1).
The number of patients with a diagnosis likely to be
associated with neuropathic pain varied between
practices, from 1 to 205 (median = 34, interquartile
range = 20–71). Recorded prevalence varied from 1.8
per 1000 to 39.6 per 1000 patients. Five hundred and
seventy-four (44%) patients had one or more of the
following co-morbidities: asthma, atrial ﬁbrillation,
coronary heart disease, cerebrovascular disease, de-
pression, hypertension, heart failure or osteoporosis.
Prescribing analysis
In total, 1089 patients (86%) had been prescribed at
least one drug used for neuropathic pain since their
diagnosis. This suggests that most of the identiﬁed
patients therefore had some degree of pain. When we
examined medication use by diagnostic group, over





Acute painful diab neuropathy 1 Herpes zoster + oth.CNS complic. 2
Asymptomatic diab neuropathy 26 Herpes zoster + other CNS compl. 70
Cerv disc disord + radiculopathy 2 Herpes zoster + other spec comp 2
Chron painful diab neuropathy 13 Lu disc prolapse + radiculopathy 31
Cx disc prolapse + radiculopathy 3 Nerve/spinal cord injuries 2
Disc prolapse + radiculopathy 1 Ophthalmic herpes zoster infec 11
Geniculate herpes zoster 9 Polyneuropathy 7
Glossopharyngeal neuralgia 2 Polyneuropathy in diabetes 76
Heredit.periph.neuropathy NOS 1 Polyneuropathy + herpes zoster 1
Herpes zost. dermatitis eyelid 1 Postinfectious polyneuritis 1
Herpes zoster 895 Postzoster neuralgia 24
Herpes zoster + unsp. complic. 2 Th disc prolapse + radiculopathy 1
Herpes zoster NOS 88 Trigeminal neuralgia NOS 44
Herpes zoster iridocyclitis 3 Trigeminal neuralgia OS 3
Herpes zoster keratoconjunctiv 4 Zoster encephalitis 1
Herpes zoster ophthalmicus 16 Other chronic pain 30
Herpes zoster + ophthalmic comp. 17
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30% of patients in these groups received a medication
from List A, considered more appropriate for neuro-
pathic pain (Table 3).
Discussion
Principal ﬁndings
This study showed that patients with a diagnosis likely
to be associated with chronic neuropathic pain can be
identiﬁed using electronic primary care records. How-
Table 2 Number of patients with READ codes associated with neuropathic pain by age
group and sex, and prevalence per 1000
Age group (years) Total no. patients Males Females Prevalence per 1000
0–14 31 20 11 0.18
15–24 69 33 36 0.50
25–34 87 44 43 0.38
35–44 109 56 53 0.60
45–54 165 68 97 1.24
55–64 261 125 136 2.88
65–74 265 126 139 4.06
75 + 274 114 160 5.35
Figure 1 Prevalence of pain-associated codes by ethnic group
Table 3 Patients on medication by diagnostic group
Diagnostic group Number of patients Number (%) on any
drug from List A
Number (%) on any
drug from List B
Herpes zoster 1038 328 (31.6) 816 (78.6)
Diabetic neuropathy 109 46 (42.6) 97 (89.8)
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ever, there wasmarked interpractice variation in coding;
this mirrors ﬁndings in studies of other chronic
conditions.16
Implications for practice
Case ﬁndings can be used to help meet national
recommendations for the management of neuropathic
pain17 through planned care, reviews and clinical
audit.10,11 Records can also be used to identify people
with neuropathic pain for use in service planning,
provision and research.
Interpractice variation suggests under-recording of
diagnoses, which will become more important as the
prevalence of neuropathic pain is expected to increase
because of an ageing population.18 Hence, further
epidemiological, clinical and therapeutic studies will
be needed. Primary care records provide a unique
opportunity for such population-based research be-
cause they cover a large population, are representative
because of the high degree of registration with GPs in
the UK, and in some practices provide near-complete
information on illness, treatments, outcomes and use
of healthcare services.19
Comparison with other studies
Prior surveys found prevalences of 3.3%5 and 8.2%8 in
their populations. Toth et al6 report a 17.9% preva-
lence in a telephone survey of 1207 randomly sampled
Canadians. This ﬁgure was higher than our and
previous studies, and may be explained by their use
of DN4Q, a validated questionnaire for chronic pain
with neuropathic symptoms. However, it has proved
diﬃcult to obtain representative samples in surveys,
for example because participants self-select or were
chosen for convenience.
Hall used the UK General Practice Research Data-
base to calculate the incidence of four syndromes
associated with chronic neuropathic pain.4 Our study
suggests that the prevalence could be calculated in this
way too, albeit with a wider range of search terms. In
line with our ﬁndings, each of these previous studies
also found the highest prevalence of chronic neuro-
pathic pain in older patients and women.
Limitations of the study
This was a cross-sectional study in an ethnically
diverse, urban area. Although the sample was repre-
sentative of the area, diﬀerent rates might be expected
in other settings. The search terms did not include
phantom limb pain but the incidence is about 1.5 per
100 000 person years, suggesting that this diagnosis
would be too uncommon to pick up in our sample.4
We also did not include carpal tunnel syndrome as the
treatment approach usually diﬀers from other neuro-
pathic pain syndromes. Other conditions omitted
include chemotherapy induced neuropathy, complex
regional pain syndrome, HIV sensory neuropathy,
neuropathy secondary to tumour inﬁltration, post-
mastectomy pain and chronic painful neuropathies
due to central nervous system conditions such as
following stroke, spinal cord injury, multiple sclerosis
and Parkinson’s disease.
We did not control for medication use for alternative
indications, for example, patients taking amitriptyline
for depression rather than pain. However, depression
is a common co-morbidity with neuropathic pain.
Similarly, future searches should incorporate measures
to account for anticonvulsants that were not pre-
scribed for pain management.
Although database searches do not identify subjects
who have not presented to the medical system, the
severe symptoms and eﬀect on quality of life make it
likely that patients would be known to primary care,
especially in the UK where many of the treatments are
available only on prescription.
Further research
If practices maintain a neuropathic pain disease regis-
ter, further work can compare the identiﬁcation rates
with control practices and estimate the deﬁcit in preva-
lence. More patients may also be identiﬁed if medi-
cation records20 and other non-diagnostic data21 are
used in the search strategy.
Electronic primary care records could also be used
to analyse the longitudinal treatment history of indi-
viduals with neuropathic pain to examine, for example,
how long patients are on suboptimal treatment before
a beneﬁcial drug or combination is found. Even patients
taking an eﬀective class of drug are often given sub-
optimal doses;3 an analysis could be constructed to
investigate this in UK primary care. Longitudinal
primary care records will also be valuable in studies
exploring the longer term outcomes of neuropathic
pain, particularly the psychosocial sequelae which are
currently less well delineated.
The NHS Care Records Service use the System-
atized Nomenclature of Medicine – Clinical Terms
(SNOMEDCT) instead of READ codes.22 SNOMED
CT codes map to deﬁnitions more accurately in other
chronic conditions such as diabetes.23 When pri-
mary care records are uploaded to the Care Records
Service, it would be interesting to see if any additional
subjects are captured using these codes from the
same population. In Europe, the main primary care
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coding system is the International Classiﬁcation of
Primary Care (ICPC).24 This could be used to com-
pare rates of neuropathic pain in similar populations
and suggest genetic or environmental trends; it may
also have implications for future coding software
choices in the UK.
Conclusion
The study illustrates that data from electronic primary
care records can be used to study neuropathic pain in a
wider population than in previous studies. We have
shown that to make full use of this valuable resource,
we need to improve the completeness and standard-
isation of coding in primary care records.
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Appendix 1 READ codes used and their text labels
READ Term READ Code READ Term READ Code
Acute painful diab neuropathy F3720 Herpes zoster + oth.CNS complic. A5310
Asymptomatic diab neuropathy F3722 Herpes zoster + other CNS compl. A531.
Cerv disc disord + radiculopathy N12zH Herpes zoster + other spec comp A53x.
Chron painful diab neuropathy F3721 Lu disc prolapse + radiculopathy N12C2
Cx disc prolapse + radiculopathy N12C0 Nerve/spinal cord injuries SJ...
Disc prolapse + radiculopathy N12C. Ophthalmic herpes zoster infec A5323
Geniculate herpes zoster A5311 Polyneuropathy F366.
Glossopharyngeal neuralgia F321. Polyneuropathy in diabetes F372.
Heredit.periph.neuropathy NOS F360z Polyneuropathy + herpes zoster F3744
Herpes zost. dermatitis eyelid A5320 Postinfectious polyneuritis F3701
Herpes zoster A53.. Postzoster neuralgia A5315
Herpes zoster + unsp. complic. A53y. Th disc prolapse + radiculopathy N12C1
Herpes zoster NOS A53z. Trigeminal neuralgia NOS F301z
Herpes zoster iridocyclitis A5322 Trigeminal neuralgia OS F301.
Herpes zoster keratoconjunctiv A5321 Zoster encephalitis A5314
Herpes zoster ophthalmicus A5324 [X]Other chronic pain Ryu70
Herpes zoster + ophthalmic comp. A532.
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Appendix 2A Medications used for all prescription analyses except those shown
in Table 2
Amitriptyline, Aspirin, Nefopam, Benolirate, Buprenorphine, BuTrans, Capsaicin, Carbamazepine Celebrex,
Co-codamol, Co-codaprin, Co-proxamol, Co-dydramol, Codeine, Dextromoramide, Diconal, Diclofenac,
Dihydrocodeine, Emﬂex, Fentanyl, Meptid, Methadone, Morphgesic, MXL, Oramorph, Oxcarbazepine,
Oxycontin, Oxynorm, Papaveretum, Pentazocine, Pethidine, Preservex, Rheumox, Seractil, MST, Oxycodone,
Gabapentin, Pregabalin, Paracetamol, Palladone, Sevredol, Temgesic, Tramadol, Transtec, Trileptal, Zomorph.
Appendix 2B Medications used in analysis presented in Table 2
List A medications
Amitriptyline, Buprenorphine, Bu Trans, Capsaicin, Carbamazepine, Cymbalta, Duragesic Duloxetine,
Fentanyl, Gabapentin, Lidocaine, Lyrica, Morphine, Morphgesic, MST, MXL, Neurontin, Nortriptyline,
Oxcarbamazepine, Oxycodone, Oxycontin, Oxynorm, Oromorph, Pregabalin, Sevredol, Temgesic, Versatis,
Tramadol, Zomorph.
List B medications – all drugs in list A plus
Aspirin, Benolirate, Celebrex, Co-codamol, Co-codaprin, Co-proxamol, Co-dydramol, Codeine,
Dextromoramide, Diconal, Diclofenac, Dihydrocodeine, Emﬂex, Meptid, Methadone, Nefopam, Papaveretum,
Pentazocine, Pethidine, Paracetamol, Palladone, Preservex, Rheumox, Seractil, Transtec.
